1-[2-(4-Cyanophenyl)ethyl]-4-(4-hydroxyphenoxymethyl)piperidin-4-ol → 1-[2-(4-Cyanophenyl)ethyl]-4-(4-hydroxyphenoxymethyl)piperidin-4-ol hydrochloride
反応式
[ClH:1].CO.[C:4]([C:6]1[CH:11]=[CH:10][C:9]([CH2:12][CH2:13][N:14]2[CH2:19][CH2:18][C:17]([CH2:21][O:22][C:23]3[CH:28]=[CH:27][C:26]([OH:29])=[CH:25][CH:24]=3)([OH:20])[CH2:16][CH2:15]2)=[CH:8][CH:7]=1)#[N:5]>CO>[ClH:1].[C:4]([C:6]1[CH:7]=[CH:8][C:9]([CH2:12][CH2:13][N:14]2[CH2:19][CH2:18][C:17]([CH2:21][O:22][C:23]3[CH:28]=[CH:27][C:26]([OH:29])=[CH:25][CH:24]=3)([OH:20])[CH2:16][CH2:15]2)=[CH:10][CH:11]=1)#[N:5]参加物
4
実験手順
10% hydrochloric acid-methanol (0.2 mL) was added to a methanol solution (2 mL) of the compound (50 mg) obtained in Step 4 of Example 1. After the solvent was removed under reduced pressure, the residue obtained was crystallized from ether and collected by filtration to obtain the titled compound (48 mg) as crystals.
後処理
- customAfter the solvent was removed under reduced pressure
- customthe residue obtained
- customwas crystallized from ether
- filtrationcollected by filtration
出典と根拠
- ORDレコード
- ord-aa80d6da31a1439097d934d520db2c33
- 出典データセット
- uspto-grants-2005_10
- 特許番号
- US06956046B2
反応ノート
読み込み中…